This biophysical regulatory mechanism, active in soft microenvironments such as primary tumors, treatment-remodeled niches, and specific metastatic sites, establishes GFAT2/HA signaling as a biomechanical driver of microenvironmental reprogramming in breast cancer. The gene discussed is GFPT2; the disease is breast cancer.